glp-1 antagonist drugs The Impact of Receptor Agonists on Sedation New GLP-1 Guidelines for Type
Description
Big thanks to our clinical team for this breakthrough innovation
Sources for Figure 218
After a few years of injectable dominance, oral formulations are emerging as a game-changer for adherence and ease of use thanks to their lack of cold-chain requirement, but also a game-changer for their ability to unlock the long-term maintenance opportunity [14]
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are peptide-derived analogs that were initially investigated to treat type 2 diabetes
A sizable proportion of patients (23.0 to 62.4%) reached an HbA1c of 1.0 vs
Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios
